WO2007149277A3 - Substituted 8-[6-amino-3-pyridyl]xanthines - Google Patents

Substituted 8-[6-amino-3-pyridyl]xanthines Download PDF

Info

Publication number
WO2007149277A3
WO2007149277A3 PCT/US2007/013849 US2007013849W WO2007149277A3 WO 2007149277 A3 WO2007149277 A3 WO 2007149277A3 US 2007013849 W US2007013849 W US 2007013849W WO 2007149277 A3 WO2007149277 A3 WO 2007149277A3
Authority
WO
WIPO (PCT)
Prior art keywords
xanthines
pyridyl
amino
substituted
compositions
Prior art date
Application number
PCT/US2007/013849
Other languages
French (fr)
Other versions
WO2007149277A2 (en
Inventor
Guoquan Wang
Robert D Thompson
Jayson M Rieger
Original Assignee
Adenosine Therapeutics Llc
Guoquan Wang
Robert D Thompson
Jayson M Rieger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UAA200900239A priority Critical patent/UA105164C2/en
Priority to DK07796049.0T priority patent/DK2029143T3/en
Application filed by Adenosine Therapeutics Llc, Guoquan Wang, Robert D Thompson, Jayson M Rieger filed Critical Adenosine Therapeutics Llc
Priority to AU2007261568A priority patent/AU2007261568B2/en
Priority to BRPI0712001A priority patent/BRPI0712001B8/en
Priority to EP07796049.0A priority patent/EP2029143B1/en
Priority to MX2008015954A priority patent/MX2008015954A/en
Priority to JP2009515468A priority patent/JP5417558B2/en
Priority to EA200900010A priority patent/EA016791B1/en
Priority to KR1020097000879A priority patent/KR101413404B1/en
Priority to ES07796049.0T priority patent/ES2548437T3/en
Priority to PL07796049T priority patent/PL2029143T3/en
Priority to CA2655598A priority patent/CA2655598C/en
Publication of WO2007149277A2 publication Critical patent/WO2007149277A2/en
Publication of WO2007149277A3 publication Critical patent/WO2007149277A3/en
Priority to IL195916A priority patent/IL195916A/en
Priority to IL195925A priority patent/IL195925A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Abstract

The present invention provides substituted 8-[6-amino-3-pyridyl]xanthines and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
PCT/US2007/013849 2006-06-16 2007-06-13 Substituted 8-[6-amino-3-pyridyl]xanthines WO2007149277A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
KR1020097000879A KR101413404B1 (en) 2006-06-16 2007-06-13 Substituted 8-[6-amino-3-pyridyl]xanthines
EA200900010A EA016791B1 (en) 2006-06-16 2007-06-13 Substituted 8-[6-amino-3-pyridyl]xanthines
AU2007261568A AU2007261568B2 (en) 2006-06-16 2007-06-13 Substituted 8-[6-amino-3-pyridyl]xanthines
DK07796049.0T DK2029143T3 (en) 2006-06-16 2007-06-13 Substituted 8- (6-amino-3-pyridyl) xanthines
EP07796049.0A EP2029143B1 (en) 2006-06-16 2007-06-13 Substituted 8-[6-amino-3-pyridyl]xanthines
MX2008015954A MX2008015954A (en) 2006-06-16 2007-06-13 Substituted 8-[6-amino-3-pyridyl]xanthines.
ES07796049.0T ES2548437T3 (en) 2006-06-16 2007-06-13 8- [6-amino-3-pyridyl] substituted xanthines
UAA200900239A UA105164C2 (en) 2006-06-16 2007-06-13 Substituted 8-[6-amino-3-pyridyl]xanthines
BRPI0712001A BRPI0712001B8 (en) 2006-06-16 2007-06-13 compound 8-[6-amino-3-pyridyl] substituted xanthines and pharmaceutical composition containing said compound
JP2009515468A JP5417558B2 (en) 2006-06-16 2007-06-13 Substituted 8- [6-amino-3-pyridyl] xanthines
PL07796049T PL2029143T3 (en) 2006-06-16 2007-06-13 Substituted 8-[6-amino-3-pyridyl]xanthines
CA2655598A CA2655598C (en) 2006-06-16 2007-06-13 Substituted 8-[6-amino-3-pyridyl]xanthines
IL195916A IL195916A (en) 2006-06-16 2008-12-14 N-{(1-cyclopropyl-3-propyl-2,6-dioxo-3,7-dihydropurin-8-yl)pyridyl} 2-pyridinecarboxamide derivatives, their use for manufacturing medicaments and intermediates obtained in a process for their preparation
IL195925A IL195925A0 (en) 2006-06-16 2008-12-15 Substituted 8-[6-amino-3-pyridyl]xanthines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80503006P 2006-06-16 2006-06-16
US60/805,030 2006-06-16
US60/805,864 2006-06-22
US11/811,823 2007-06-12

Publications (2)

Publication Number Publication Date
WO2007149277A2 WO2007149277A2 (en) 2007-12-27
WO2007149277A3 true WO2007149277A3 (en) 2008-02-21

Family

ID=38833978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/013849 WO2007149277A2 (en) 2006-06-16 2007-06-13 Substituted 8-[6-amino-3-pyridyl]xanthines

Country Status (4)

Country Link
CN (1) CN101466382A (en)
UA (1) UA105164C2 (en)
WO (1) WO2007149277A2 (en)
ZA (1) ZA200900259B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009118759A2 (en) 2008-03-26 2009-10-01 Advinus Therapeutics Pvt. Ltd., Heterocyclic compounds as adenosine receptor antagonist
WO2010103547A2 (en) 2009-03-13 2010-09-16 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
JP5843778B2 (en) 2009-11-09 2016-01-13 アドヴィナス・セラピューティックス・リミテッド Substituted fused pyrimidine compounds, their preparation and their use
CA2810625C (en) 2010-09-13 2018-01-23 Advinus Therapeutics Private Limited Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065341A1 (en) * 2003-08-25 2005-03-24 Guoquan Wang Substituted 8-heteroaryl xanthines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065341A1 (en) * 2003-08-25 2005-03-24 Guoquan Wang Substituted 8-heteroaryl xanthines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2029143A4 *

Also Published As

Publication number Publication date
CN101466382A (en) 2009-06-24
UA105164C2 (en) 2014-04-25
WO2007149277A2 (en) 2007-12-27
ZA200900259B (en) 2010-09-29

Similar Documents

Publication Publication Date Title
WO2006091898A3 (en) Pyrazolyl substituted xanthines
WO2005021548A3 (en) Substituted 8-heteroaryl xanthines
MY152178A (en) Substituted 8-[6-amino-3-pyridyl]xanthines
IL178396A0 (en) Condensed pyridine derivatives useful as a28 adenosine receptor antagonists
IL188725A0 (en) Pyrazine derivatives useful as adenosine receptor antagonists
WO2000073307A8 (en) Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors
ZA200802588B (en) Imidazopyridine derivatives as A2B adenosine receptor antagonists
WO2007122591A3 (en) Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists
ATE481409T1 (en) THIAZOLOPYRAMIDINE/PYRIDINE UREA DERIVATIVES AS ANTAGONISTS AT THE ADENOSINE A2B RECEPTOR
WO2008031556A3 (en) 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
IL178365A0 (en) Selective antagonists of a2a adenosine receptors
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
WO2007090071A3 (en) 6-modified bicyclic nucleic acid analogs
IL182528A0 (en) Purine derivatives for use as adenosin a-2a receptor antagonists
ATE461932T1 (en) PYRAZOLOÄ4,3-EÜ-1,2,4-TRIAZOLOÄ1,5-CUPYRIMIDINES AS ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR
ZA200801945B (en) Novelimidazolecarboxamide derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
WO2006091936A3 (en) Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2009082720A3 (en) Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9h-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as a2ar agonists
WO2008011007A3 (en) Selective antagonists of a2a adenosine receptors
HK1131392A1 (en) Adenosine derivatives as a2a receptor agonists
WO2008021849A3 (en) Novel compounds as antagonists or inverse agonists at opioid receptors
ZA200902187B (en) 8-Ethinylxanthine derivatives as selective A2A receptor antagonists
WO2006028810A3 (en) Method of wound healing using a2b adenosine receptor antagonists
EP1734966A4 (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists
WO2005040155A8 (en) Pyrimidin-2-amine derivates and their use as a2b adenosine receptor antagonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780022207.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07796049

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 12008502653

Country of ref document: PH

Ref document number: 2007261568

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007796049

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009515468

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2008/015954

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 195916

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 195925

Country of ref document: IL

Ref document number: 2655598

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 573872

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2762/MUMNP/2008

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2007261568

Country of ref document: AU

Date of ref document: 20070613

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200900010

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1020097000879

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: RU

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: PI0712001

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081215